Sign up to our newsletter Subscribe
The Value of Knowing and Knowing the Value: Improving the Health Technology Assessment of Complementary Diagnostics

Sign up to our newsletter Subscribe
Biosimilars have similar, but not identical, structures to branded biologic drugs. Being comparable, but not interchangeable, they can differ in cost-effectiveness and accessibility. Increased competition, however, can reduce healthcare system costs.
An error has occurred, please try again later.